Abstract:OBJECTIVE Insulin resistance is a key characteristic of first-degree relatives of patients with type 2 diabetes. We therefore treated young, glucose-tolerant relatives with the insulin action enhancer troglitazone in order to determine the effects on insulin sensitivity, glucose metabolism, and glycogen synthase activity. RESEARCH DESIGN AND METHODS Relatives were randomized in a double-blind manner and treated for 12 weeks with either 200 mg troglitazone or placebo. Before and after treatment, an oral glucose tolerance test (OGTT) and a euglycemic-hyperinsulinemic clamp (40 mU. m(-2). min(-1)) were performed, including 3-(3)H glucose infusion, glycolytic flux calculations, indirect calorimetry, and muscle biopsies. RESULTS Twelve relatives received troglitazone and 12 placebo (aged 30.8 +/- 2.0 vs. 30.3 +/- 1.6 years, BMI 29.6 +/- 0.8 vs. 30.5 +/- 1.3 kg/m(2); means +/- SE). Area under the curve (AUC) for plasma glucose at the second OGTT was unchanged after troglitazone. In contrast, troglitazone reduced fasting (from 70.3 +/- 6.9 to 52.2 +/- 5.8 vs. 73.6 +/- 11.0 to 73.3 +/- 6.5 pmol/l, P < 0.02) and AUC plasma insulin (mean [CI] from 335.7 [230.9-488.1] to 277.4 [179.4-428.8] vs. 313.8 [218.2-451.2] to 353.9 [208.3-601.3] pmol/l, P < 0.05). Additionally, fasting plasma triglycerides were reduced by troglitazone (from 1.86 +/- 0.33 to 1.38 +/- 0.27 vs. 2.22 +/- 0.44 to 2.35 +/- 0.46 mmol/l, P < 0.01). Insulin-stimulated glucose disposal increased in the troglitazone group (from 208.3 +/- 23.7 to 263.5 +/- 30.4 vs. 197.1 +/- 20.0 to 200.8 +/- 20.8 mg. m(-2). min(-1), P < 0.02) mainly due to increased glucose storage (from 99.9 +/- 17.9 to 146.0 +/- 25.3 vs. 87.1 +/- 16.7 to 87.9 +/- 15.7 mg. m(-2). min(-1), P < 0.02), which took place without altering insulin-stimulated glycogen synthase activity. CONCLUSIONS In glucose-tolerant first-degree relatives, treatment with troglitazone improved insulin sensitivity almost 50%, primarily due to increased glucose storage. It is suggested that the use of insulin action enhancers can be especially valuable in this group of subjects with a known high risk for developing type 2 diabetes.

Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.

Competitive markets for individual health insurance

Horizontal and Vertical Equity and Public Subsidies for Private Health Insurance in the U.S.

Insomnia disorder is associated with increased amygdala reactivity to insomnia-related stimuli.

Attachment of steroidogenic lipid droplets to intermediate filaments in adrenal cells.

Individual insurance: health insurers try to tap potential market growth

More options, more problems? Lost in the health insurance maze

When Should There Be Vertical Choice in Health Insurance Markets?

Cutaneous Mucinosis of Infancy: A Congenital and Linear Variant

Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment.

Radioactivity in the Uteri of Rats Following Injection of Estrone-16-C14 ∗

Health Insurance, Market Power, and Social Welfare

Understanding cardiac "echo" reports. Practical guide for referring physicians.

Estimating Equilibrium in Health Insurance Exchanges: Price Competition and Subsidy Design under the ACA

Is Broader Health Insurance Coverage Always Better?

Expanding Enrollment Without the Individual Mandate: Options to Bring More People into the Individual Market

Phylogenetic evidence for horizontal transfer of an intervening sequence between species in a spirochete genus

Constructing health consumers: Private health insurance discourses in Australia and the United Kingdom

Demand heterogeneity in insurance markets: Implications for equity and efficiency

A tax reform strategy to deal with the uninsured

Managed competition in the United States: How well is it promoting equity and efficiency?